| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 10.2 | 6.8 |
| Gross profit | 8.5 | 5.2 |
| Profit before tax | -4.8 | -12.4 |
| Net income | -4.8 | -12.4 |
| EPS (diluted, $ a share) | $-0.05 | $-0.12 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +48.7% |
|---|---|
| Gross margin | 83.4% |
| Operating margin | -59.5% |
10-Q filed with the SEC, NASDAQ: MXCT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Maxcyte, Inc.: key numbers
- Share price
- $1.18Close, Nov 16
- Market cap
- $122M
- Shares outstanding
- 103.25MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Commercial Physical & Biological ResearchSIC 8731
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Maxcyte, Inc.
All →Maxcyte Signs $125M M&A Deal with Akron BioProducts LLC
MaxCyte has entered into a definitive agreement to acquire Akron BioProducts LLC for $105 million in cash, $20 million in deferred cash payments, and approximately 20.6 million shares of common stock. The acquisition of the GMP-grade reagent supplier is expected to nearly double MaxCyte's revenue and expand its cell therapy manufacturing offerings. The deal is expected to close before the end of 2026, subject to regulatory approvals.
- Value
- $125M
- Counterparty
- Akron BioProducts LLC
“Today, we announced our intention to acquire Akron Bio, a transformational moment for MaxCyte. I believe combining MaxCyte and Akron will expand our commercial opportunity, strengthen our financial profile, and drive long-term value.”
Maher Masoud, President and CEO of MaxCyte
Maxcyte Business Update
MaxCyte announced preliminary Q3 2026 core business revenue of approximately $8.1 million, a 26% year-over-year increase. The company also raised its full-year 2026 total revenue guidance to approximately $34 million, up from the previous range of $30 million to $32 million, driven by accelerated instrument purchasing and milestone payments.